| 價(jià)格 | 詢價(jià) |
| 包裝 | 1支 |
| 最小起訂量 | 1支 |
| 發(fā)貨地 | 湖北 |
| 更新日期 | 2026-07-08 |
| 中文名稱:HLA-DRA (4K6)兔單抗 | 英文名稱:HLA-DRA (4K6) Rabbit Monoclonal Antibody |
| 品牌: EnkiLife | 產(chǎn)地: 中國 |
| 產(chǎn)品類別: 抗體 | |
| 是否進(jìn)口: 否 | 用途: 科研 |
產(chǎn)品概述
產(chǎn)品性能
免疫原
產(chǎn)品應(yīng)用
研究背景
HLA-DRA is one of the HLA class II alpha chain paralogues. This class II molecule is a heterodimer consisting of an alpha and a beta chain, both anchored in the membrane. It plays a central role in the immune system by presenting peptides derived from extracellular proteins. Class II molecules are expressed in antigen presenting cells (APC: B lymphocytes, dendritic cells, macrophages). An alpha chain of antigen-presenting major histocompatibility complex class II (MHCII) molecule. In complex with the beta chain HLA- DRB, displays antigenic peptides on professional antigen presenting cells (APCs) for recognition by alpha-beta T cell receptor (TCR) on HLA-DR-restricted CD4-positive T cells. This guides antigen-specific T- helper effector functions, both antibody-mediated immune response and macrophage activation, to ultimately eliminate the infectious agents and transformed cells (PubMed:29884618, PubMed:17334368, PubMed:8145819, PubMed:15322540, PubMed:22327072, PubMed:27591323, PubMed:31495665, PubMed:15265931, PubMed:9075930, PubMed:24190431). Typically presents extracellular peptide antigens of 10 to 30 amino acids that arise from proteolysis of endocytosed antigens in lysosomes (PubMed:8145819). In the tumor microenvironment, presents antigenic peptides that are primarily generated in tumor-resident APCs likely via phagocytosis of apoptotic tumor cells or macropinocytosis of secreted tumor proteins (PubMed:31495665). Presents peptides derived from intracellular proteins that are trapped in autolysosomes after macroautophagy, a mechanism especially relevant for T cell selection in the thymus and central immune tolerance (PubMed:17182262, PubMed:23783831). The selection of the immunodominant epitopes follows two processing modes: 'bind first, cut/trim later' for pathogen-derived antigenic peptides and 'cut first, bind later' for autoantigens/self- peptides (PubMed:25413013). The anchor residue at position 1 of the peptide N-terminus, usually a large hydrophobic residue, is essential for high affinity interaction with MHCII molecules (PubMed:8145819).
研究領(lǐng)域
| 成立日期 | 2024-08-02 (2年) | 注冊(cè)資本 | 271萬人民幣 |
| 員工人數(shù) | 10-50人 | 年?duì)I業(yè)額 | ¥ 100萬-300萬 |
| 主營行業(yè) | 生化試劑,抗體,細(xì)胞培養(yǎng),癌癥研究,細(xì)胞生物學(xué) | 經(jīng)營模式 | 工廠,試劑,定制,服務(wù) |
| 產(chǎn)品名稱 | 價(jià)格 | 公司名稱 | 報(bào)價(jià)日期 | |
|---|---|---|---|---|
| ¥1138 |
VIP4年
|
上海滬震實(shí)業(yè)有限公司
|
2026-07-28 | |
| ¥1600.00 |
VIP11年
|
北京索萊寶科技有限公司
|
2026-07-28 | |
| 詢價(jià) |
湖北瑞和寧生物科技有限公司
|
2025-05-10 |